Inhibikase Therapeutics shares surge 11.52% intraday after H.C. Wainwright & Co. issues buy rating with $8.00 target and plans phase III trials for IKT-001 in Q1 2026.
ByAinvest
Friday, Dec 26, 2025 10:40 am ET1min read
IKT--
Inhibikase Therapeutics surged 11.52% intraday, as H.C. Wainwright & Co. issued a buy rating with an $8.00 target price on December 26, 2025, and the company announced plans to initiate phase III trials for its pulmonary arterial hypertension drug IKT-001 in Q1 2026. The company focuses on developing treatments for Parkinson’s disease and pulmonary arterial hypertension.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet